New targets for drug development in asthma (Q37274728)

19 August 2017

1 reference

title

New targets for drug development in asthma (English)

1 reference

19 August 2017

0 references

Ian M Adcock

1

0 references

author name string

Gaetano Caramori

series ordinal

2

1 reference

PubMed ID

18805336

19 August 2017

K Fan Chung

series ordinal

3

1 reference

PubMed ID

18805336

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

372

1 reference

19 August 2017

1073-1087

1 reference

19 August 2017

9643

1 reference

The global burden of asthma: executive summary of the GINA Dissemination Committee report

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

1 reference

7 January 2021

Asthma: defining of the persistent adult phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Pathogenesis of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Inhaled glucocorticoids for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Update on glucocorticoid action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Inhaled corticosteroids: impact on asthma morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Mechanisms involved in the side effects of glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Compliance, adherence, and concordance: implications for asthma treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

RETRACTED: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Epithelial cell proliferation contributes to airway remodeling in severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Specificity of basement membrane thickening in severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Cluster analysis and clinical asthma phenotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

An electronic nose in the discrimination of patients with asthma and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

New therapies for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Comparative effects of inhaled budesonide and the NO-donating budesonide derivative, NCX 1020, against leukocyte influx and airway hyperreactivity following lipopolysaccharide challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Treatment of asthma with antileukotrienes: first line or last resort therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

1 reference

7 January 2021

Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Leukocyte navigation mechanisms as targets in airway diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Chemokine-receptor expression on T cells in lung compartments of challenged asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

New molecular targets for the treatment of neutrophilic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Novel drug development opportunities for heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Adenovirus IL-13-induced airway disease in mice: a corticosteroid-resistant model of severe asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

New drugs targeting Th2 lymphocytes in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Attenuated production of intracellular IL-10 and IL-12 in monocytes from patients with severe asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Haplotype associated with low interleukin-10 production in patients with severe asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Evidence of a role of tumor necrosis factor alpha in refractory asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

The effect of telithromycin in acute exacerbations of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Clarithromycin targets neutrophilic airway inflammation in refractory asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Toll-like receptors--novel targets in allergic airway disease (probiotics, friends and relatives).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Development and application of Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Phosphodiesterase inhibitors in airways disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Kinase inhibitors and airway inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Corticosteroid-insensitive asthma: molecular mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Allergen-induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N-terminal kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

PI 3-kinase inhibition: a therapeutic target for respiratory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Activation and localization of transcription factor, nuclear factor-kappaB, in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

The role of IkappaB kinase 2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-gamma-stimulated human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Decreased histone deacetylase activity in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

How corticosteroids control inflammation: Quintiles Prize Lecture 2005

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Gene expression of the GATA-3 transcription factor is increased in atopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Regulation of GATA-3, c-maf and T-bet mRNA expression in bronchoalveolar lavage cells and bronchial biopsies after segmental allergen challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Therapeutic approaches for control of transcription factors in allergic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Cytokine signaling modules in inflammatory responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Molecular determinants of crosstalk between nuclear receptors and toll-like receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Theophylline and dexamethasone induce peroxisome proliferator-activated receptor-gamma expression in human eosinophils

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Oxidative stress promotes polarization of human T cell differentiation toward a T helper 2 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Nitrative stress in refractory asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Selective Inducible Nitric Oxide Synthase Inhibition Has No Effect on Allergen Challenge in Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Regulation of inflammation and redox signaling by dietary polyphenols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Clinical studies with curcumin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

1 reference

7 January 2021

Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Mechanisms of allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961449-X

7 January 2021

10.1016/S0140-6736(08)61449-X

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18805336